Obesity data weigh on Pfizer shares, but growing pipeline has multiple catalysts

The latest data for Pfizer’s recently acquired Metsera obesity asset confirm the potential for once-monthly dosing, but likely will require higher doses to differentiate from other programs in development.

In parallel with announcing its 4Q25 earnings, Pfizer Inc. (NYSE:PFE) disclosed data from the Phase IIb VESPER-3 study of PF-08653944 (MET-097i) to treat obesity. In the study, patients received 12 weekly doses of PF-’944 followed by 16 weeks of once-monthly doses. ...